Technosphere® Insulin (TI) is a novel inhalation powder for the treatment of diabetes mellitus. Technosphere Insulin delivers insulin with an ultra rapid pharmacokinetic profile that is distinctly different from all other insulin products but similar to natural insulin release. Such rapid absorption is often associated with penetration enhancers that disrupt cellular integrity.
Methods:
Technosphere Insulin was compared to a panel of known penetration enhancers in vitro using the Calu-3 lung cell line to investigate the effects of TI on insulin transport.
Results:
Measures of tight junction integrity such as transepithelial electrical resistance, Lucifer yellow permeability, and F-actin staining patterns were all unaffected by TI. Cell viability and plasma membrane integrity were also not affected by TI. In contrast, cells treated with comparable (or lower) concentrations of penetration enhancers showed elevated Lucifer yellow permeability, disruption of the F-actin network, reduced cell viability, and compromised plasma membranes.
Conclusions:
These results demonstrate that TI is not cytotoxic in an in vitro human lung cell model and does not function as a penetration enhancer. Furthermore, TI does not appear to affect the transport of insulin across cellular barriers.
KrysiakRGdula-DymekABednarska-CzerwinskaAOkopienB. Growth hormone therapy in children and adults. Pharmacol Rep.2007;59 (5): 500–16.
2.
ChesnutCHIIIAzriaMSilvermanSEngelhardtMOlsonMMindeholmL. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int.2008;19 (4): 479–91.
3.
BrownLR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv.2005;2 (1): 29–42.
4.
DaughertyALMrsnyRJ. Emerging technologies that overcome biological barriers for therapeutic protein delivery. Expert Opin Biol Ther.2003;3 (7): 1071–81.
5.
ClelandJLDaughertyAMrsnyR. Emerging protein delivery methods. Curr Opin Biotechnol.2001;12 (2): 212–9.
6.
YuJChienYW. Pulmonary drug delivery: physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst.1997;14 (4): 395–453.
7.
SayaniAPChienYW. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst.1996;13 (1–2): 85–184.
8.
WearleyLL. Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst.1991;8 (4): 331–94.
9.
HollanderPA. Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes. MedGenMed.2007;9 (1): 45.
10.
GhoshSCollierA. Inhaled insulins. Postgrad Med J.2007;83 (977): 178–81.
11.
PattonJSByronPR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov.2007;6 (1): 67–74.
12.
SkylerJS. Pulmonary insulin delivery—state of the art 2007. Diabetes Technol Ther.2007;9 (Suppl 1): S1–3.
BrainJD. Inhalation, deposition, and fate of insulin and other therapeutic proteins. Diabetes Technol Ther.2007;9Suppl 1: S4–15.
15.
BahhadyRKimKJBorokZCrandallEDShenWC. Enhancement of insulin transport across primary rat alveolar epithelial cell monolayers by endogenous cellular factor(s). Pharm Res.2007;24 (9): 1713–9.
16.
KimKJMatsukawaYYamaharaHKalraVKLeeVHCrandallED. Absorption of intact albumin across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol.2003;284 (3): L458–65.
17.
PezronIMitraRPalDMitraAK. Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3). J Pharm Sci.2002;91 (4): 1135–46.
18.
HussainAAhsanF. Indication of transcytotic movement of insulin across human bronchial epithelial cells. J Drug Target.2006;14 (4): 181–90.
19.
HussainAArnoldJJKhanMAAhsanF. Absorption enhancers in pulmonary protein delivery. J Control Release.2004;94 (1): 15–24.
20.
PattonJSFishburnCSWeersJG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc.2004;1 (4): 338–44.
PfütznerAMannAESteinerSS. Technosphere/insulin—a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther.2002;4 (5): 589–94.
23.
SteinerSPfütznerAWilsonBRHarzerOHeinemannLRaveK. Technosphere/Insulin—proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes.2002;110 (1): 17–21.
24.
PfütznerAForstT. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv.2005;2 (6): 1097–106.
25.
KaurNZhouBBreitbeilFHardyKKarftKSTrantchevaIPhanstielOIV. A delineation of diketopiperazine self-assembly processes: understanding the molecular events involved in Nepsilon-(fumaroyl)diketopiperazine of L-Lys (FDKP) interactions. Mol Pharm.2008;5 (2): 294–315.
26.
AnderbergEKArturssonP. Epithelial transport of drugs in cell culture. VIII: effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells. J Pharm Sci.1993;82 (4): 392–8.
27.
AnderbergEKLindmarkTArturssonP. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm Res.1993;10 (6): 857–64.
28.
AnderbergEKNyströmCArturssonP. Epithelial transport of drugs in cell culture. VII: effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. J Pharm Sci.1992;81 (9): 879–87.
29.
Cano-CebriánMJZornozaTGraneroLPolacheA. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv.2005;2 (1): 9–22.
30.
CoyneCBRibeiroCMBoucherRCJohnsonLG. Acute mechanism of medium chain fatty acid-induced enhancement of airway epithelial permeability. J Pharmacol Exp Ther.2003;305 (2): 440–50.
31.
HurniMANoachABBlom-RoosemalenMCde BoerAGNagelkerkeJFBreimerDD. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy. J Pharmacol Exp Ther.1993;267 (2): 942–50.
32.
SakaiMImaiTOhtakeHAzumaHOtagiriM. Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy. J Pharm Sci.1997;86 (7): 779–85.
33.
Salamat-MillerNJohnstonTP. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm.2005;294 (1–2): 201–16.
34.
ShonoYNishiharaHMatsudaYFurukawaSOkadaNFujitaTYamamotoA. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci.2004;93 (4): 877–85.
35.
SteimerAHaltnerELehrCM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med.2005;18 (2): 137–82.
36.
SakagamiM. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev.2006;58 (9–10): 1030–60.
37.
GraingerCIGreenwellLLLockleyDJMartinGPForbesB. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res.2006;23 (7): 1482–90.
38.
ForbesBEhrhardtC. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm.2005;60 (2): 193–205.
39.
FloreaBICassaraMLJungingerHEBorchardG. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release.2003;87 (1–3): 131–8.
40.
MathiaNRTimoszykJStetskoPIMegillJRSmithRLWallDA. Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J Drug Target.2002;10 (1): 31–40.
41.
FosterKAAveryMLYazdanianMAudusKL. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm.2000;208 (1–2): 1–11.
42.
WangZZhangQ. Transport of proteins and peptides across human cultured alveolar A549 cell monolayer. Int J Pharm.2004;269 (2): 451–6.
43.
GeysJCoenegrachtsLVercammenJEngelborghsYNemmarANemeryBHoetPH. In vitro study of the pulmonary translocation of nanoparticles: a preliminary study. Toxicol Lett.2006;160 (3): 218–26.
